The MYG1 Knockout LoVo Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the MYG1 gene in the LoVo human colorectal adenocarcinoma cell line. This product provides a heterogeneous pool of edited cells that can be used to study loss-of-function effects of MYG1 without the constraints of clonal selection. As a polyclonal population, these cells represent a direct outcome of pooled editing, offering a versatile tool for functional genomics and pathway analysis in a colorectal cancer context. The CRISPR/Cas9-mediated gene disruption abrogates MYG1 expression, enabling researchers to investigate its role in cell cycle regulation and tumor biology.
LoVo cells are an adherent, epithelial cell line originally established from a lymph node metastasis of a 56-year-old male patient with colon adenocarcinoma. This cell line has been extensively employed as an in vitro model for studying colon cancer proliferation, metastasis, and drug resistance. LoVo cells harbor well-characterized signaling aberrations, including constitutive activation of the MAPK/ERK pathway, making them particularly relevant for dissecting oncogenic mechanisms. Their metastatic origin also positions them as a suitable system for evaluating genes implicated in advanced colorectal cancer progression.
MYG1 encodes a putative cell cycle regulator that promotes cell proliferation and may possess RNA binding activity. Within the signaling network, MYG1 operates downstream of the MITF transcription factor and ERK1/2 signaling. Activation of MYG1 is predicted to transcriptionally upregulate cyclin D1 and CDK4, thereby facilitating G1/S phase transition through pRB phosphorylation. Predicted downstream targets also include PCNA, consistent with a role in DNA replication and cell cycle progression. The mechanistic summary suggests that MYG1 disruption attenuates cyclin D1 and CDK4 activity, leading to impaired cell growth. Although interacting factors remain unknown, MYG1 integrates signals from the MITF transcriptional network and MAPK/ERK pathway to coordinate proliferative responses.
In the context of colorectal cancer, MYG1 knockout in LoVo cells provides a physiologically relevant model to examine the gene’s contribution to tumor cell proliferation. Given that LoVo cells already exhibit dysregulated ERK signaling, this model allows dissection of MYG1-dependent mechanisms within a disease-relevant background. The knockout is expected to reduce cell cycle progression, offering a platform to study the dependency of colorectal cancer cells on MYG1 for sustained growth. This model is particularly valuable for validating therapeutic targets and understanding resistance mechanisms in colon adenocarcinoma.
This polyclonal knockout cell population is suitable for a range of functional assays, including MTT proliferation assay, BrdU incorporation, flow cytometry-based cell cycle analysis, RT-qPCR for downstream targets such as cyclin D1 and CDK4, western blotting for cyclin D1, CDK4, and pRB, and colony formation assay. Researchers can employ this model to investigate MYG1 function in colorectal cancer, validate the gene as a drug target, or screen for compounds that modulate MYG1-dependent signaling. For further technical information and ordering, please contact Ascent Research.
